Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

Core Insights - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, an antibody therapy targeting KIT (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][3] Company Overview - Jasper is conducting clinical studies of briquilimab, which is a targeted aglycosylated monoclonal antibody that inhibits signaling through the KIT receptor, leading to mast cell depletion via apoptosis [3] - The company has reported positive clinical outcomes for briquilimab in patients with CSU, CIndU, and allergic asthma, demonstrating both efficacy and safety [3] Upcoming Events - Jasper will participate in the 46th Annual TD Cowen Healthcare Conference from March 2-4, 2026, with a presentation scheduled for March 2, 2026, at 3:50 PM EST in a fireside chat format [2]